Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
about
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromesPP2A: The Achilles Heal in MDS with 5q DeletionDelayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndromeLong-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.Current therapy of myelodysplastic syndromesRibosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implicationsRibosomopathies: mechanisms of disease.Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesThe relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromesPhase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expressionTP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesMyelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.p53 and ribosome biogenesis stress: the essentials.Update on the pharmacotherapy for myelodysplastic syndromes.The molecular pathogenesis of the myelodysplastic syndromes.Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment.Recent Advances in the 5q- Syndrome.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromesUBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights.RP-MDM2-p53 Pathway: Linking Ribosomal Biogenesis and Tumor Surveillance.Molecular action of lenalidomide in lymphocytes and hematologic malignanciesp53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.FGFR2 mutations in bent bone dysplasia syndrome activate nucleolar stress and perturb cell fate determination.Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.Genetic susceptibility to thalidomide embryopathy in humans: Study of candidate development genesdeletion in luminal cells of mature prostate induces replication stress and senescence in vivo
P2860
Q26778754-AE361154-2CA5-4BB2-B399-EDDFF61CCEECQ27690852-3B217244-DED8-4B4C-AA6E-43686D8CBCB4Q28831412-FFF98E11-253E-4772-8239-58F36635A94AQ33675946-ADB24E6D-4A9B-4961-9871-8665FB548512Q34013796-2A63CD98-88F7-4082-BE7A-AA2A9EE82B50Q34435519-6AE58195-E8BA-4713-A211-0746F9215110Q34454066-F2D4F40E-20C6-4DAC-8819-438F92CF3D55Q34627728-D907B87C-5DF0-4E94-A233-A97AD1A47B1DQ34783754-D84BCF48-F961-46E0-8E69-B4BA2CCF1323Q35244865-F40736B3-56B7-49CC-811E-718842699D10Q36474572-2AE5B6A7-1B21-46A2-8FA9-04076B88D81DQ36544120-A51E67D4-AA93-47CF-88A8-E5045BF8E791Q37014078-587FD93C-2FD5-420A-AD33-7CBA3DD592A7Q37074311-FF7005A5-1EA2-479A-985E-0725864868A2Q37079785-A46A7755-4211-4760-ACB5-7E820A23910BQ37218274-02624E14-8700-4379-960C-B23C4B038570Q38047020-FD753A1C-1D39-4177-A0C6-A930F7DE870AQ38135713-4B08CD20-6045-41BD-9E28-87601F6C16E5Q38195796-F9018147-7551-4A51-9D95-EA92AF10B5C6Q38205676-6393A5EE-BACF-46FC-85C2-8130E86AD84BQ38235662-4AFC0EFC-FFA6-4B1C-8BA7-9CC36BB4C311Q38341998-E29723FB-CACD-4160-9652-F76D1DB8292EQ38451022-E8261E93-5F13-43A9-8668-714403DC3654Q38527837-76FF35BA-C244-4882-8282-FC7118AE259AQ38687894-93CEB114-ADC3-463A-9318-6369C0D3FA5DQ38764824-A58300CC-4929-4A8A-813D-88DB55BF5C28Q38941587-31D99513-3456-48C9-A7BF-241DF99803DBQ39069357-69812D72-14D9-4847-AEAB-DCA1D7B5A8A9Q39456968-1285141A-0A8F-407C-8E7D-4F864B37DD67Q39570166-24FE53E7-1601-40E1-A080-84B3BF2AACC8Q40382947-CFBE2CAA-2C8D-4250-922E-7277408DC8FAQ43441639-D83BC19E-69F6-4CF5-9750-0FEB5ACC0445Q45155324-32D92381-33D8-4EB2-AB81-E500976145ABQ52777531-C0CCF724-4F40-4E18-A220-26BD90D6141AQ53339839-53FA0D29-61BD-4DA4-81E7-3626F6C69692Q54204985-7450023E-28F7-40FB-ABBF-3F99DC544557Q56786087-9FF41FEA-2A69-442F-808C-014F86820CB9Q57848625-67A890AD-7FFD-4F8F-9C5D-3D9E9132E93E
P2860
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Lenalidomide promotes p53 degr ...... me with chromosome 5q deletion
@en
Lenalidomide promotes p53 degr ...... me with chromosome 5q deletion
@nl
type
label
Lenalidomide promotes p53 degr ...... me with chromosome 5q deletion
@en
Lenalidomide promotes p53 degr ...... me with chromosome 5q deletion
@nl
prefLabel
Lenalidomide promotes p53 degr ...... me with chromosome 5q deletion
@en
Lenalidomide promotes p53 degr ...... me with chromosome 5q deletion
@nl
P2093
P2860
P356
P1433
P1476
Lenalidomide promotes p53 degr ...... me with chromosome 5q deletion
@en
P2093
D Billingsley
J P Maciejewski
P2860
P2888
P304
P356
10.1038/ONC.2012.139
P407
P577
2012-04-23T00:00:00Z
P6179
1005348672